Glutamate (Glu) is the most abundant excitatory neurotransmitter in the central nervous system (CNS) and is involved in the pathophysiology of Alzheimer’s disease (AD) in which there is an increased excitotoxicity. Biochemical composition of living tissues including the levels of Glu was analyzed by magnetic resonance spectroscopy (MRS). Previous reports point to decreased levels of Glu in AD. As Glu plays an important role in memory, we hypothesize that Glu levels are decreased in patients with AD when compared with controls. A consecutive sample of 30 patients with mild-to-moderate AD underwent H-MRS with the voxel placed in the bilateral posterior cingulate gyrus. For comparison purposes, we carried out the same technique in 68 patients with mild cognitive impairment (MCI) and in 26 controls. The healthy controls had higher metabolite levels of N-acetyl-aspartate (NAA) than patients with MCI and AD. In turn, patients with MCI and the controls had higher levels of Glu than in patients with AD. The differences were significant in the analysis of variance (ANOVA) test model corrected for age. In the post hoc analysis, the most remarkable differences were seen between patients with AD and the rest (patients with MCI and the controls). In AD, the levels of Glu and NAA are decreased in comparison with MCI and normality, which reflects loss of neurons.
ParsonsCGDanyszWQuackG. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology. 1999;38(6):735–767.
4.
LiptonSA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRX. 2004;1(1):101–110.
5.
ReisbergBDoodyRStofflerA. Memantine in moderate to severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341.
6.
AreosaSASherriffFMcShaneR. Memantine for dementia. Cochrane Database Syst Rev. 2005;18(2):CD003154.
7.
PeskindERPotkinSGPomaraN. For the memantine MEM-MD-10 study group. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704–715.
8.
BackchineSLoftH. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomized, duble-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11(4):471–479.
9.
SalekRMXiaJInnesA. A metabolic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int. 2010;56(8):937–947.
10.
AntuonoPGJonesJLWangYLiSJ. Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology. 2002;56(6):737–742.
11.
HattoriNAbeKSakodaSSawadaT. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport. 2002;13(1):183–186.
12.
RupsinghRBorrieMSmithMWellsJLBarthaR. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging. 2009;32(5):802–810.
13.
SoherBJDoraiswamyPMCharlesHC. A review of 1H MR spectroscopy findings in Alzheimer’s disease. Neuroimaging Clin N Am. 2005;15(4):847–852.
14.
ModregoPJFayedNPinaMA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry. 2005;162(4):667–675.
15.
ModregoPJFayedNErreaJMRiosCPinaMASarasaM. Memantine versus donepezil in Alzheimer’s disease. A randomized trial with magnetic resonance spectroscopy. Eur J Neurol. 2010;17(3):405–412.
16.
FayedNDávilaJOliverosACastilloJMedranoJJ. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol. 2008;15(9):1089–1098.
17.
KantarciKWeigandSDPetersenRC. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2007;28(9):1330–1339.
18.
BucknerRLAndrews-HannaJRSchacterDL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1 124:1–38.
BuschkeHKuslanskyGKatzM. Screening for dementia with the memory impairment screen. Neurology. 1999;52(2):231–238.
21.
LoboAEzquerraJGomez BurgadaFSalaJMSeva DiazA. Cognocitive mini-test (a simple practical test to detect intellectual changes in medical patients [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1979;7(3):189–202.
22.
McKhanGDrachmanDFolsteinMKatzmanRPriceDStadlanEM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group. Neurology. 1984;34(7):939–944.
23.
ProvencherSW. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672–679.
24.
DanielsenERRossB. Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York, NY: Marcel Dekker; 1999:5–22.
25.
FayedNModregoPJMedranoJ. Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software. Neurol Res. 2009;31(5):472–477.
26.
MatsudaH. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med. 2001;15(2):85–92.
27.
SperlingRADickersonBCPihlajamakiM. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010;12(1):27–43.
28.
ModregoPFayedNSarasaM. Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort. BMJ Open 2011. doi: 10.1136/bmjopen-2010-000007;
KantarciKXuYShiungMM. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14(4):198–207.
31.
ValenzuelaMJSachdevP. Magnetic resonance spectroscopy in AD. Neurology. 2001;56(5):592–598.
32.
HorskaAKaufmannWBrantLNaiduSHarrisJBarkerP. In vivo quantitative proton MRSI study of brain development from childhood to adolescence. J Magn Reson Imaging. 2002;15(2):137–143.
33.
FayedNDávilaJOliverosAJrMedranoJCastilloJ. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment. Neurol Res. 2010;32(2):157–165.
34.
BleichSRömerKWiltfangJKornhuberJ. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry. 2003;18(suppl 1):S33–S40.
35.
OguraAMiyamotoMKudoY. Neuronal death in vitro: parallelism between survivability of hippocampal neurones and sustained elevation of cytosolic Ca2+ after exposure to glutamate receptor agonist. Exp Brain Res. 1988;73(3):447–458.
36.
MattsonMPMurrainMGuthriePBKaterSB. Fibroblast growth factor and glutamate: opposing roles in the generation and degeneration of hippocampal neuroarchitecture. J Neurosci. 1989;9(11):3728–3740.
37.
GazullaJCavero-NagoreM. Glutamato y enfermedad de Alzheimer. Rev Neurol. 2006;42(7):427–432.
38.
RowlandLMBustilloJRMullinsPG. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005;162(2):394–396.
39.
ZahrNMMayerDPfefferbaumASullivanEV. Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy. Cereb Cortex. 2008;18(10):2241–2250.
40.
SperlingRALaviolettePSO’KeefeK. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178–188.
LiuSJGasperiniRFoaLSmallDH. Amyloid-β decreases cell surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2. J Alzheimer’s Dis. 2010;21(2):655–666.
43.
ParodiJSepúlvedaFJRoaJOpazoCInestrosaNCAguayoLG. Amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol chem. 2010;285(4):2506–2514.
